Press release

Filter by:

Latest

Filing of eight patent applications on proprietary GalNAc-siRNA technology and target related innovation

Aug 1, 2022

Result of Annual General Meeting

Jul 20, 2022

Director Dealing and Issue of Equity

Jul 5, 2022

Notice of Annual General Meeting and Posting of Annual Report and Accounts

May 17, 2022

Final results for the year ended 31 January 2022

May 4, 2022

Key Milestone Achieved and Significant Progress on Galapagos Collaboration

Apr 12, 2022

Immuno-Oncology Research Collaboration with iTeos Therapeutics

Apr 5, 2022

Senior Management Update

Nov 22, 2021

Interim results for six months ended 31 July 2021

Oct 26, 2021

RNAi Platform Characterisation Results

Oct 26, 2021

Investor Presentation

Oct 20, 2021

Patent Filing Applications

Oct 11, 2021

Notice of Interim Results

Oct 11, 2021

Commencement of trading on the OTCQX Best Market

Sep 24, 2021

Further milestone in Galapagos collaboration

Jul 2, 2021

Senior Management Appointment and Options Grant

Jun 2, 2021

Results of conditional Fundraise to raise £22.5 million

May 14, 2021

Retail Offer

May 13, 2021

Proposed Fundraise in excess of £20 million

May 13, 2021

Final Results for the Year Ended 31 January 2021

May 13, 2021

Notification of Full Year Results Date

May 6, 2021

ETX to receive two payments from Galapagos

Apr 23, 2021

Appointment of Chief Financial Officer

Mar 29, 2021

Change of Adviser

Mar 1, 2021